more than 55 kg and up to 85 kg: 390 mg [3 vials]

Comparison of Efficacy and Safety between Standard and Intensive Ustekinumab Treatment for Patients with Moderate to Severe Luminal Crohn’s disease who Show a Non-response or a Loss of Response to TNF Inhibitors

Efficacy of Early 4-Week Interval Dosing of Ustekinumab in Patients with Moderate to Severe Luminal Crohn’s disease who Show a Non-response or a Loss of Response to TNF Inhibitors